BMS Jettisons Coronary Trial for J&J-Partnered Anticoagulant
Bristol Myers Squibb (BMS) has discontinued a major coronary clinical trial evaluating a J&J (Janssen)-partnered anticoagulant, which was part of a collaboration program for Factor XIa inhibitors, including BMS-986177713.
The decision to terminate the trial marks a significant development in the partnership between BMS and Janssen, impacting the clinical advancement of novel oral anticoagulants targeting thrombotic cardiovascular conditions27.
The background to this collaboration centers on developing anticoagulants with a potentially improved efficacy and bleeding risk profile compared to existing factor Xa inhibitors; ongoing programs aimed to address large patient populations at risk for conditions like acute coronary syndrome25.
BMS and Janssen had planned to share development costs and commercial profits and losses for this class of drugs, with a broad clinical development strategy underway before the discontinuation news2.
Recent company presentations and investor material still cite the overall development program, but the specific coronary indication trial (likely LIBREXIA-ACS) has been halted57.
This move fits with recent trends at BMS to streamline its pipeline and terminate partnerships or programs seen as less likely to deliver strong clinical or commercial success3.
Sources:
2. https://www.bms.com/life-and-science/news-and-perspectives/collaboration-with-janssen.html
3. https://www.fiercebiotech.com/biotech/bms-pushes-fulcrum-its-list-partners-scrapping-myokardia-heart-muscle-pact
5. https://www.bms.com/assets/bms/us/en-us/pdf/investor-info/doc_presentations/2025/BMS-JPM-2025-presentation.pdf
7. https://www.biospace.com/fda/fda-faces-catastrophic-collapse-as-massive-layoffs-endanger-user-fee-program
13. https://www.biospace.com/press-releases/regeneron-highlights-progress-at-american-society-of-hematology-ash-with-updated-data-in-multiple-myeloma-lymphoma-and-paroxysmal-nocturnal-hemoglobinuria-programs